Tradestie Institutional Equity Comparison Engine
XBIO vs IMDX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
XBIO Overall Edge
XBIO Captures Institutional Edge (3โ0 Pillars ยท 3โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Xenetic Biosciences, Inc. (XBIO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, XBIO trades at N/M Forward P/E with -81.0% operating margin (+12.0% YoY revenue) versus IMDX at N/M Forward P/E and -1883.2% operating margin (+115.0% YoY). In options structure, XBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against IMDX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
XBIO N/M vs IMDX N/M Fwd P/E
Growth & Margin Winner
XBIO
Op Margin -81.0% vs -1883.2% ยท YoY +12.0% vs +115.0%
Momentum & Technical Winner
XBIO
1Y -40.1% vs -73.8% ยท 52W Pos 3% vs 3%
Options & Structure Winner
XBIO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (12th %ile IV)
XBIO
NASDAQ
Xenetic Biosciences, Inc.
Pharmaceutical Preparations
$1.54
+0.65% 1D
Market Cap
$3.6M
1M Return
-23.76%
1Y Return
-40.08%
Forward P/E
N/M
Unified AI Score
52.8 / 100
HOLD
Tech 58.0
Fund 53.0
Flow 50.0
Mom 60.0
IMDX
NASDAQ
Insight Molecular Diagnostics Inc. Common Stock
In Vitro & In Vivo Diagnostic Substances
$1.66
+4.4% 1D
Market Cap
$52.1M
1M Return
-45.03%
1Y Return
-73.78%
Forward P/E
N/M
Unified AI Score
45.5 / 100
HOLD
Tech 50.0
Fund 40.0
Flow 58.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
XBIO -40.08%
IMDX -73.78%
Spread: +33.7 pp (XBIO Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | XBIO Revenue | IMDX Revenue | XBIO Op. Margin | IMDX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2017 | $10M | N/A | -47.1% | N/A | XBIO |
| FY2019 | $0M | N/A | -75511.7% | N/A | XBIO |
| FY2020 | $0M | $0M | -3189.8% | -2443.3% | IMDX |
| FY2021 | $0M | $0M | -495.1% | -2444.3% | XBIO |
| FY2022 | $0M | $0M | -393.6% | -1878.6% | XBIO |
| FY2023 | $0M | $0M | -177.8% | -1672.4% | XBIO |
| FY2024 | $0M | $0M | -168.2% | -3245.1% | XBIO |
| FY2025 | $0M | $0M | -95.2% | -1260.8% | XBIO |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XBIO | IMDX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $3.6M | $52.1M | Larger Scale | IMDX |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +12.0% | +115.0% | Higher Growth | IMDX |
| Operating Margin (TTM) Profitability | -81.0% | -1883.2% | Higher Margin | XBIO |
| Net Profit Margin Profitability | -75.9% | 0.0% | Higher Margin | IMDX |
| Return on Equity (ROE) Capital Efficiency | -47.0% | -23603.1% | Higher ROE | XBIO |
| 52-Week Range Position Momentum | 3% ($1โ$5) | 3% ($2โ$8) | Stronger Trend | Tie |
| Beta / 30D Volatility Risk Regime | 1.54ฮฒ ยท 99% Vol | 2.91ฮฒ ยท 76% Vol | Lower Realized Risk | IMDX |
| Unified Institutional Score Composite Signal | 52.8 / 100 (HOLD) | 45.5 / 100 (HOLD) | Higher Composite | XBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full XBIO vs IMDX Buy Guide
XBIO
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
IMDX
BREAKDOWN
117d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
12th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither XBIO nor IMDX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.